The speaker has seen many platform companies pivot toward drug development while retaining a platform business, using discovered drug candidates to support the case for further investment.

“So I saw so many of these platform companies pivoting at some point to, "We make a drug." And yeah, at the side, of course, we have our, our sort of virtual cell, whatever business, but you know, we have two drugs that we found and now this, so if we put a lot of money in, um, maybe you have some other counting sums.”